News blog

Omega Diagnostics

  • BY: Andrew Hore |
  • POSTED: 08/03/2019 |

Omega Diagnostics appears to be on course to gain a CE Mark for its Visitect CD4 HIV diagnostic test by the end of March. 

Visitect CD4 has significant potential with the main customers non-government organisations working in Africa and Asia.

Small orders have already been secured for the test from Indonesia, Moldova and Papua New Guinea. Ethics approval has been gained from the Nigerian authorities for a performance evaluation. Nigeria could be the largest potential market for the test.

There is nothing in the forecasts for Visitect CD4 revenues in the year to March 2019 and there are no 2019-20 forecasts, although there are expected to be meaningful revenues for the test next year. 

© 2019 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

News Blog
All micro news

Northern Bear

Roofing and building services provider Northern Bear directors say they will not accept the 72p a share tender offer from Cedarvale Holdings. 

Continue reading... | 21/10/2019

LiDCO Group

Patient monitoring devices supplier LiDCO increased its product revenues by 10% in the year to July 2019. 

Continue reading... | 21/10/2019

Quoted Micro 14 October 2019

Continue reading... | 14/10/2019

Hague and London Oil

Former Aim company Hague and London Oil reported a decline in revenues in the first half of 2019, but it moved from loss to profit, but this was due to a gain on derivative instruments. 

Continue reading... | 13/10/2019

All micro news

Browse by issue
All issues
Popular tags
All tags

betbrokers, financial, gold, health, leisure, media, mobile, resources, services, technology

AIM Micro feeds

Keep up to date with articles published at Subscribe to AIM Micro RSS Feeds